U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines

• Published in: Vaccine Vol. 39; no. 28; pp. 3666 - 3677
• Main Authors: Gubernot, Diane, Jazwa, Amelia, Niu, Manette, Baumblatt, Jane, Gee, Julianne, Moro, Pedro, Duffy, Jonathan, Harrington, Theresa, McNeil, Michael M., Broder, Karen, Su, John, Kamidani, Satoshi, Olson, Christine K., Panagiotakopoulos, Lakshmi, Shimabukuro, Tom, Forshee, Richard, Anderson, Steven, Bennett, Sarah
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 23.06.2021; Elsevier Limited; Elsevier Science
• Subjects: Adverse events; Age groups; Background rates; Collaboration; Coronaviruses; COVID-19; COVID-19 Vaccines; Critical components; Disease; Disease control; Epidemiology; Federal government; Global health; Guillain-Barre syndrome; Health surveillance; Humans; Immunization; Incidence; Incidence rates; Lipids; Literature reviews; Medicare; Minority & ethnic groups; mRNA; Nanoparticles; Pandemics; Platforms; Population; Public health; Review; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Social interactions; Surveillance; Swine flu; United States - epidemiology; Vaccination; Vaccine safety; Vaccines; Vaccines - adverse effects; Viral diseases; United States; United States > US; California; COVID-19; Incidence rates; Vaccine safety; Adverse events; Surveillance; Background rates
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2021.05.016

The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid further social and economic disruption. Mass vaccination campaigns are underway in multiple countries and are expected worldwide once more vaccine becomes available. Some early candidate vaccines use novel platforms, such as mRNA encapsulated in lipid nanoparticles, and relatively new platforms, such as replication-deficient viral vectors. While these new vaccine platforms hold promise, limited safety data in humans are available. Serious health outcomes linked to vaccinations are rare, and some outcomes may occur incidentally in the vaccinated population. Knowledge of background incidence rates of these medical conditions is a critical component of vaccine safety monitoring to aid in the assessment of adverse events temporally associated with vaccination and to put these events into context with what would be expected due to chance alone. A list of 22 potential adverse events of special interest (AESI), including neurologic, autoimmune, and cardiovascular disorders, was compiled by subject matter experts at the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention. The most recently available U.S. background rates for these medical conditions, overall and by age, sex, and race/ethnicity (when available), were sourced from reported statistics (data published by medical panels/ associations or federal government reports), and literature reviews in PubMed. This review provides estimates of background incidence rates for medical conditions that may be monitored or studied as AESI during safety surveillance and research for COVID-19 vaccines and other new vaccines.